[Congressional Record Volume 162, Number 21 (Thursday, February 4, 2016)]
[Daily Digest]
[Pages D106-D107]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

Committee Meetings
NAVAL STRIKE FIGHTERS: ISSUES AND CONCERNS
Committee on Armed Services: Subcommittee on Tactical Air and Land 
Forces held a hearing entitled ``Naval Strike Fighters: Issues and 
Concerns''. Testimony was heard from Lieutenant General Jon M.

[[Page D107]]

Davis, USMC, Deputy Commandant of the Marine Corps for Aviation 
(DC(A)), U.S. Marine Corps; Rear Admiral Michael C. Manazir, USN, 
Director, Air Warfare Division (N98), U.S. Navy; and Rear Admiral 
Michael T. Moran, USN, Program Executive Officer Tactical Aircraft, 
U.S. Navy.
THE CONGRESSIONAL BUDGET OFFICE'S BUDGET AND ECONOMIC OUTLOOK
Committee on the Budget: Full Committee held a hearing entitled ``The 
Congressional Budget Office's Budget and Economic Outlook''. Testimony 
was heard from Keith Hall, Director, Congressional Budget Office.
EXAMINING IMPLEMENTATION OF THE BIOLOGICS PRICE COMPETITION AND 
INNOVATION ACT
Committee on Energy and Commerce: Subcommittee on Health held a hearing 
entitled ``Examining Implementation of the Biologics Price Competition 
and Innovation Act''. Testimony was heard from Sean Cavanaugh, Deputy 
Administrator and Director of the Center of Medicare, Centers for 
Medicare and Medicaid Services; and Janet Woodcock, Director, Center 
for Drug Evaluation and Research, Food and Drug Administration.
ANOTHER SURGE OF ILLEGAL IMMIGRANTS ALONG THE SOUTHWEST BORDER: IS THIS 
THE OBAMA ADMINISTRATION'S NEW NORMAL?
Committee on the Judiciary: Subcommittee on Immigration and Border 
Security held a hearing entitled ``Another Surge of Illegal Immigrants 
Along the Southwest Border: Is this the Obama Administration's New 
Normal?''. Testimony was heard from Steven McCraw, Director, Texas 
Department of Public Safety; and public witnesses.
DEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT
Committee on Oversight and Government Reform: Full Committee held a 
hearing entitled ``Developments in the Prescription Drug Market: 
Oversight''. Testimony was heard from Janet Woodcock, Director, Center 
for Drug Evaluation and Research, Food and Drug Administration; Keith 
Flanagan, Director, Office of Generic Drug Policy, Food and Drug 
Administration; and public witnesses.
A REVIEW OF RECOMMENDATIONS FOR NSF PROJECT MANAGEMENT REFORM
Committee on Science, Space, and Technology: Subcommittee on Research 
and Technology; and Subcommittee on Oversight, held a joint hearing 
entitled ``A Review of Recommendations for NSF Project Management 
Reform''. Testimony was heard from Richard Buckius, Chief Operating 
Officer, National Science Foundation; Allison Lerner, Inspector 
General, National Science Foundation; and a public witness.
BUSINESS MEETING
Committee on Small Business: Full Committee held a markup on Views and 
Estimates on the President's FY 2017 Budget for the Small Business 
Administration. The Views and Estimates were adopted.
BUSINESS MEETING
Permanent Select Committee on Intelligence: Full Committee held a 
business meeting on consideration of a Committee Report. The Committee 
Report was adopted. A portion of the meeting was closed.

Joint Meetings
  No joint committee meetings were held.